View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
July 16, 2019updated 12 Jul 2022 12:28pm

Janssen to trial mosaic-based HIV-1 preventive vaccine

Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium of partners is set to initiate a Phase III clinical trial to evaluate an investigational preventive vaccine for HIV-1 infection.

Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium of partners is set to initiate a Phase III clinical trial to evaluate an investigational preventive vaccine for HIV-1 infection.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The mosaic-based vaccine has been designed to target a broad range of HIV viral strains.

Named Mosaico, the study will be launched later this year. It expects to enrol 3,800 participants at 55 sites in eight countries across North America, South America and Europe.

The trial will assess the efficacy of Janssen’s vaccine in men who have sex with men (MSM) and transgender people.

The investigational vaccine, backed by Janssen’s AdVac adenovirus vector platform, will be administered via four vaccinations over a year.

It consists of four adenovirus serotype 26 vectors that deliver mosaic HIV antigens, Ad26.Mos4.HIV, and a combination of Mosaic and Clade C trimeric gp140 proteins adjuvanted using aluminium phosphate.

Janssen Vaccines & Prevention will sponsor the trial. The National Institute of Allergy and Infectious Diseases (NIAID) and the US Army Medical Research and Development Command (USAMRDC) will provide funding support.

The HIV Vaccine Trials Network (HVTN) will support the implementation of the trial.

Johnson & Johnson chief scientific officer and executive committee vice-chairman Paul Stoffels said: “Our vision at Johnson & Johnson is to develop a preventive vaccine that can be deployed anywhere, worldwide, to halt the HIV epidemic.

“No single organisation can tackle this historic challenge alone. By working with our global partners and leveraging cutting-edge technologies, we are optimistic that we can achieve an HIV vaccine in our lifetime.”

Mosaico follows a proof-of-concept Phase IIb efficacy trial called Imbokodo that is investigating a mosaic-based vaccine regimen in 2,600 women aged 18-35 years in five southern African countries.

Initial data from Imbokodo and Mosaico are anticipated to be reported in 2021 and 2023, respectively.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena